Posted on

During ASCO, Breaking Data asked 30 oncologists to select which checkpoint inhibitor offers the best risk-benefit ratio in aNSCLC. The chart depicts the number of oncologists (out of 30) that believe KEYTRUDA® offers the best risk-benefit ratio compared with OPDIVO® and TECENTRIQ®.

Source: Breaking Data: 2018 American Society of Oncology (ASCO) Impact Analysis Report: Solid Tumors

advanced non-small cell lung cancer (aNSCLC)

Quote Icon
There may not be a huge difference, but pembro was the first to demonstrate efficacy in combo with chemo. -Community Oncologist

Stay Connected with Hem/Oncs at ASH 2020

Learn More